HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bjork, V. O. Articles by Henze, A. Search for Related Content PubMed PubMed Citation Articles by Bjork, V. O. Articles by Henze, A.

The Journal of Thoracic and Cardiovascular Surgery, Vol 78, 331-342, Copyright © 1979 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Ten years' experience with the Bjork-Shiley tilting disc valve

VO Bjork and A Henze

More than 10 years of clinical experience with 1,800 consecutive valve replacements with the Bjork-Shiley tilting disc valve were focused on improving its durability, flow dynamics, thromboresistance, and in vivo functional control. Although the original Delrin disc functions excellently after 10 years in the human circulation, the durability of the prosthetic valve was further prolonged by the introduction of pyrolytic carbon as disc material. The opening mechanism was also reinforced by integrating the bearing struts with the valve ring. No other presently available heart valve prosthesis shows such a low resistance to flow for a given tissue diameter. The disc was equipped with a ring-shaped radiopaque marker that permitted noninvasive functional control. The 5 year survival rates were 82% after aortic, 66% after mitral, and 66% after mitral and aortic valve replacements, including the operative mortality rates. The incidence of systemic emboli was 0.7% per year after aortic, 4.2% per year after mitral, and 2.2% per year after mitral and aortic valve replacements with anticoagulation treatment. The incidence of obstruction by thrombosis was 0.3% per year for aortic, 1.3% per year for mitral, and 2.3% per year tricuspid prostheses. The new convex-concave model decreases the stagnation zone behind the disc, decreases emboli from 4.2% to 1.2% per year after mitral valve replacement, and has a lower gradient.

This article has been cited by other articles:

				T. Abe, K. Kamata, K. Kuwaki, K. Komatsu, and S. Komatsu Ten Years' Experience of Aortic Valve Replacement With the Omnicarbon Valve Prosthesis Ann. Thorac. Surg., April 1, 1996; 61(4): 1182 - 1187. [Abstract] [Full Text]

				M. H. Eckman, H. J. Levine, and S. G. Pauker Effect of Laboratory Variation in the Prothrombin-Time Ratio on the Results of Oral Anticoagulant Therapy N. Engl. J. Med., September 2, 1993; 329(10): 696 - 702. [Abstract] [Full Text]

				M. H. Eckman, J. R. Beshansky, I. Durand-Zaleski, H. J. Levine, and S. G. Pauker Anticoagulation for Noncardiac Procedures in Patients With Prosthetic Heart Valves: Does Low Risk Mean High Cost? JAMA, March 16, 1990; 263(11): 1513 - 1521. [Abstract] [PDF]

				A. Starr and G. L. Grunkemeier Selection of a Prosthetic Heart Valve JAMA, April 6, 1984; 251(13): 1739 - 1742. [Abstract] [PDF]

				S. H. RAHIMTOOLA The Need for Cardiac Catheterization and Angiography in Valvular Heart Disease is NotDisproven Ann Intern Med, September 1, 1982; 97(3): 433 - 439. [Abstract] [PDF]